Find, compare & contact
Taberminogene vadenovec API Manufacturers & Suppliers

teaser-1024x654-1
Contact suppliers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Taberminogene vadenovec is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Taberminogene vadenovec or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Taberminogene vadenovec API 943980-47-0?

Description:
Here you will find a list of producers, manufacturers and distributors of Taberminogene vadenovec. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Taberminogene vadenovec 
Synonyms:
 
Cas Number:
943980-47-0 
DrugBank number:
DB05011 

General Description:

Taberminogene vadenovec, identified by CAS number 943980-47-0, is a notable compound with significant therapeutic applications. Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs after vascular surgery. The initial target market is haemodialysis graft access surgery, a procedure in which patients whose kidneys have failed have a plastic tube grafted between blood vessels generally in their forearm so that their blood can be regularly filtered using a dialysis machine. EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC).

Indications:

This drug is primarily indicated for: Investigated for use/treatment in cardiovascular disorders and kidney disease. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Mechanism of Action:

Taberminogene vadenovec functions by: EG004 is a combination of a vascular endothelial growth factor (VEGF-D) gene packaged in an adenoviral vector (Ad 5) and a bio-degradable local drug delivery device made from collagen and invented by Ark. At the end of access graft surgery, the delivery device is fitted around the outside of the patient's vein where it has been joined to the access graft. The adenoviral vector carrying the VEGF gene is then injected into a space between the device and the blood vessel. This unique administration of the gene to the outside of the blood vessel rather than into the blood supply localises delivery of the gene to the target tissue site (smooth muscle cells) and reduces the risk of unwanted systemic effects. Once the VEGF gene is transfected locally, muscle cells in the vessel wall produce the VEGF protein which triggers the release of beneficial nitric oxide and prostacyclin. Ark has made a novel discovery by showing that the VEGF protein working via these two agents has a protective effect in vivo, keeping blood vessel walls in a healthy state and regulating muscle cell growth to prevent blocking of the vessel. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Taberminogene vadenovec is a type of Emollients and protectives


Emollients and protectives are an essential category of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in various topical formulations. These substances play a crucial role in protecting and moisturizing the skin, making them widely utilized in the pharmaceutical and cosmetic industries.

Emollients are substances that help restore and maintain the skin's natural moisture barrier, preventing water loss and promoting hydration. They act by forming a thin film on the skin's surface, reducing transepidermal water loss (TEWL) and improving the skin's texture and elasticity. Common emollients include natural oils, such as jojoba oil, almond oil, and shea butter, as well as synthetic compounds like mineral oil and petrolatum.

Protectives, on the other hand, are API ingredients that shield the skin from harmful external factors, such as irritants, allergens, and environmental pollutants. They create a physical barrier that prevents the penetration of harmful substances into the skin. Protectives are often combined with emollients to provide a dual function of hydration and protection.

The applications of emollients and protectives are vast and encompass a wide range of pharmaceutical and cosmetic products. They are commonly found in moisturizers, creams, lotions, ointments, balms, and sunscreens. These APIs are especially beneficial for individuals with dry or sensitive skin, as they can soothe irritation, reduce redness, and alleviate discomfort.

In conclusion, emollients and protectives are vital categories of pharmaceutical APIs that provide hydration and protection to the skin. Their versatile applications make them crucial ingredients in a wide array of topical formulations, contributing to the overall health and well-being of the skin.